The Guardian | Oct 23 | A weak pound helped GSK post growth in revenues and earnings per share that exceeded expectations. But on constant exchange rate terms, the company saw a decline of 3% in sales overall and 13% in US sales as many of its products reached the "generic cliff.” click here

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.